Article

Long-term mavacamten exposure reduces force and sarcomere density in a hiPSC model of hypertrophic cardiomyopathy

2025-10-15

Abstract excerpt

<h4>Background</h4> Mavacamten, a first-in-class allosteric myosin inhibitor, has demonstrated efficacy and safety in obstructive hypertrophic cardiomyopathy (oHCM), notably reducing symptoms, left ventricular outflow obstruction, and wall thickness over 30 weeks. We recently reported that the MYBPC3 :c.772G>A variant causes HCM through cMyBP-C haploinsufficiency, leading to accelerated sarcomere kinetics and hi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2d4d035d-54e5-5afd-bc86-43ed83d0d043
DOI: 10.1101/2025.10.14.681400

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Long-term mavacamten exposure reduces force and sarcomere density in a hiPSC model of hypertrophic cardiomyopathyDOI 10.1101/2025.10.14.681400Read

Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatmentSemantic proximity Read

Human iPSC-CMs and in-silico technologies define mechanisms and accelerate targeted pharmacogenetics in hypertrophic cardiomyopathySemantic proximity Read

Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.Semantic proximity Read

Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy.Semantic proximity Read

cMyBP-C ablation in human engineered cardiac tissue causes progressive Ca2+-handling abnormalities.Semantic proximity Read

Titin-truncating variants in hiPSC cardiomyocytes induce pathogenic proteinopathy and sarcomere defects with preserved core contractile machinerySemantic proximity Read

Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.Semantic proximity Read

Length-dependent hypercontractility decoupled from cellular adaptations is the initial phenotype in MYBPC3-haploinsufficient iPSC-derived engineered cardiac tissuesSemantic proximity Read

Altered contractility in mutation-specific hypertrophic cardiomyopathy: a mechano-energetic in silico study with pharmacological insightsSemantic proximity Read

Broad therapeutic benefit of myosin inhibition in hypertrophic cardiomyopathySemantic proximity Read

Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline.Semantic proximity Read

<i>MYBPC3</i> D389V Variant Induces Hypercontractility in Cardiac OrganoidsSemantic proximity Read